<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669030</url>
  </required_header>
  <id_info>
    <org_study_id>SVX-IIT2016-001</org_study_id>
    <nct_id>NCT02669030</nct_id>
  </id_info>
  <brief_title>A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia</brief_title>
  <official_title>A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Advanced Medical Research, Alpharetta, GA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Augusta University, Dept. of Psychiatry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Advanced Medical Research, Alpharetta, GA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression with ongoing insomnia is a common clinical presentation with patients. Clinical&#xD;
      data suggests that patients with insomnia that receive concomitant treatment with a sleep aid&#xD;
      experience a more robust antidepressant response along with a quicker response. The purpose&#xD;
      of this clinical study is to compare the effectiveness of the FDA-approved insomnia&#xD;
      medication suvorexant, also known as Belsomra®, as add-on treatment to an antidepressant to&#xD;
      that of placebo plus antidepressant treatment in patients with depression and residual or&#xD;
      ongoing insomnia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many patients with depression suffer from residual insomnia. This study is a six week,&#xD;
      randomized, double-blind, placebo-controlled, trial to study suvorexant augmentation of&#xD;
      continuing antidepressant therapy against placebo with continuing antidepressant therapy.&#xD;
      Patient volunteers must be on a stable antidepressant treatment and will remain on this&#xD;
      treatment for the duration of the study. Patient volunteers that qualify and enroll in the&#xD;
      clinical trial will either receive suvorexant 10 mg/day and may have it adjusted to a dose of&#xD;
      either 15 mg or 20 mg/day. Treatment is for a total of six weeks in addition to a clinical&#xD;
      follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time</measure>
    <time_frame>Six weeks ( baseline to end of treatment)</time_frame>
    <description>assessment of total amount of time spent sleeping</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>Six weeks ( baseline to end of treatment)</time_frame>
    <description>assessment of insomnia severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>Six weeks ( baseline to end of treatment)</time_frame>
    <description>assessment fo depressive symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale</measure>
    <time_frame>Six weeks ( baseline to end of treatment)</time_frame>
    <description>assessment of impact of symptoms on performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake After Sleep Onset (WASO)</measure>
    <time_frame>Six weeks ( baseline to end of treatment)</time_frame>
    <description>assessment of amount of time spent awake after initial onset of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Latency (SL)</measure>
    <time_frame>Six weeks ( baseline to end of treatment)</time_frame>
    <description>assessment of amount of time it takes to fall asleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Deficits Questionnaire (PDQ)</measure>
    <time_frame>Six weeks ( baseline to end of treatment)</time_frame>
    <description>a brief patient-rated scale to assess subjective cognitive dysfunction in people with depression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>MDD</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no augmentation of FDA-approved antidepressant treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suvorexant</intervention_name>
    <description>an FDA-approved sleep aid</description>
    <arm_group_label>Suvorexant</arm_group_label>
    <other_name>Belsomra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>control group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written Informed Consent&#xD;
&#xD;
          -  Diagnosis of depression (MDD)&#xD;
&#xD;
          -  Currently on antidepressant&#xD;
&#xD;
          -  Healthy and/or stable medically&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unwilling to discontinue current use of sedative hypnotics/sleep aids/benzodiazepines&#xD;
             or over the counter sleep aids/supplements&#xD;
&#xD;
          -  currently using other psychotropics other than antidepressants&#xD;
&#xD;
          -  at risk of self harm or a suicide attempt within the past 12 months&#xD;
&#xD;
          -  history or presence of psychotic disorders&#xD;
&#xD;
          -  known hypersensitivity to suvorexant&#xD;
&#xD;
          -  presence of any other sleep disorder other than residual insomnia of depression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Sambunaris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Advanced Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandon Lenfest, BS</last_name>
    <phone>770-817-9200</phone>
    <email>info@iamresearch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Advanced Medical Research @ Mercer Univeristy</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Kerlin, BS</last_name>
      <phone>770-817-9200</phone>
      <email>info@iamresearch.org</email>
    </contact>
    <investigator>
      <last_name>Angelo Sambunaris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of GA at Augusta Univeristy</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vaughn McCall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

